Results of Alnylam’s HELIOS-B trial could affect care — and impact stock price of Pfizer and BridgeBio, which offer competing therapies.
Advertisement
STAT+
Your go-to source for the world of life sciences, medicine, and biopharma. Subscribe now.Cancel anytime.
Subscribe nowMore From STAT
More From STAT
More From STAT
STAT offers a variety of in-person and virtual events throughout the year.
All Events
26
Sep
Washington, DC September 26, 2024
STAT in DC is back this fall. As the election nears, STAT will sit down with lawmakers and industry leaders for a discussion on policy and its impact on our health care system.
More From STAT
More From STAT
More From STAT
We create tools to help you understand and track complex areas of development.
All Trackers
Here are the dozens of weight loss drugs in development to catch a booming market.
Follow the latest developments in genome editing.
A guide to the health systems and companies driving adoption.
An authoritative database of FDA’s fast-tracked medical devices.
Mon - Fri
Your daily dose of news in health and science
Our Picks
Our Picks
STAT’s selection of must-read stories and investigations
a stat investigation
a stat investigation
